Dongsung biopharmaceutical with 60 years of history provides customer-oriented total services and future-oriented marketing which covers cosmetics and finished medicine.
Dongsung Pharmaceutical's rehabilitation plan rejected
Dongsung Pharmaceutical's rehabilitation plan was rejected at a creditors' meeting. The company has applied for forced approval and will disclose the results promptly.
Dongsung Pharma fined for illegal rebates to hospitals
Dongsung Pharmaceutical fined by Fair Trade Commission for providing 250 million won in illegal rebates to 4 hospitals over 8 years. Company ordered to cease practice but spared monetary penalty due to ongoing restructuring.
Taekwang Industry and UAMCO consortium acquires Dongsung Pharmaceutical
Taekwang Industry and UAMCO consortium acquire Dongsung Pharmaceutical, expanding into beauty and healthcare. Taekwang aims to strengthen its portfolio beyond chemicals and textiles.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.